Cel-Sci
CVM
#9791
Rank
C$66.39 M
Marketcap
C$7.90
Share price
-1.19%
Change (1 day)
-54.15%
Change (1 year)

P/E ratio for Cel-Sci (CVM)

P/E ratio as of February 2026 (TTM): -0.5000

According to Cel-Sci 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.5. At the end of 2025 the company had a P/E ratio of -1.41.

P/E ratio history for Cel-Sci from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2025-1.41-33.53%
2024-2.1223.59%
2023-1.71-56.82%
2022-3.97-67.67%
2021-12.3-18.35%
2020-15.018.13%
2019-12.7458.29%
2018-2.28151.14%
2017-0.9071-69.29%
2016-2.95117.84%
2015-1.36-23.69%
2014-1.78-64.46%
2013-5.000%
2012-5.0072.97%
2011-2.89-116.76%
201017.3-400.42%
2009-5.74-4.3%
2008-6.00-4.76%
2007-6.301.61%
2006-6.20-46.09%
2005-11.5-14.81%
2004-13.5125%
2003-6.001066.67%
2002-0.5143-81.91%
2001-2.84

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
21.8-4,465.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
26.2-5,336.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Xencor
XNCR
-6.86 1,272.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-0.2411-51.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
53.7-10,849.20%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
BioCryst Pharmaceuticals
BCRX
-130 25,940.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
8.17-1,734.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-0.0159-96.82%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.